Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...
The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
Including Tecentriq (atezolizumab) to Tecentriq plus Avastin (bevacizumab) and tiragolumab remedy didn't present an additional advantage in sufferers with untreated domestically superior...
Loqtorzi (disitamab vedotin plus toripalimab-tpzi) demonstrated a statistically vital enchancment in survival in contrast with standard-of-care chemotherapy as a frontline therapy for...
Including Tecentriq to chemo resulted in survival outcomes similar to placebo plus chemo in sufferers with superior or recurrent endometrial most cancers,...
The addition of the oral AKT inhibitor Truqap (capivasertib) to Zytiga (abiraterone acetate), prednisone and androgen deprivation remedy (ADT) prolonged investigator-assessed radiographic...
Amongst sufferers with high-risk, HER2-positive main breast most cancers with residual invasive illness following neoadjuvant remedy, remedy with Enhertu (fam-trastuzumab deruxtecan-nxki; T-DXd)...
